Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avastin unraveled by stratification study, Roche seeks validation

This article was originally published in Scrip

Executive Summary

  • Reanalysis of Avastin registration trial brings Roche strategy for making universal Avastin use in oncology into question again.
  • Study suggests less than half of Avastin treated colorectal cancer patients benefit from the drug.
  • Similar stratification may be demonstrated in other Avastin indication.
  • UK’s National Health Service could benefit financially from running confirmatory study.
  • Since Avastin is approved and reimbursed in colorectal cancer in many market, the UK where reimbursement is not automatic is one of the few markets where such a trial could be performed ethically.
  • You may also be interested in...


    Gender Diversity In Pharma: Caught Between Desire And Reality

    Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

    Women In High Places: Slow Progress In Pharma

    With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

    Stock Scan April 2018: Pharma's Fizz Falls Flat

    In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.





    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts